Related Experiment Video
Updated: May 17, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific
James R Tysome1, Xiaozhu Li, Shengdian Wang
1Sino-British Research Center for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
Purpose:
The efficacy of oncolytic viruses depends on multiple actions including direct tumor lysis, modulation of tumor perfusion, and stimulation of tumor-directed immune responses. In this study, we investigated whether a sequential combination of immunologically distinct viruses might enhance antitumor efficacy through the induction of tumor-specific immunity and circumvention or mitigation of antiviral immune responses.
Experimental Design:
The Syrian hamster as an immune-competent model that supports replication of both adenovirus and vaccinia virus was evaluated in vitro and in vivo. The antitumor efficacy of either virus alone or sequential combination of the two viruses was examined in pancreatic and kidney cancer models. The functional mechanism of the regimen developed here was investigated by histopathology, immunohistochemistry staining, CTL assay, and T-cell depletion.
Results:
The Syrian hamster is a suitable model for assessment of oncolytic adenovirus and vaccinia virus. Three low doses of adenovirus followed by three low doses of vaccinia virus resulted in a superior antitumor efficacy to the reverse combination, or six doses of either virus alone, against pancreatic and kidney tumors in Syrian hamsters. A total of 62.5% of animals bearing either tumor type treated with the sequential combination became tumor-free, accompanied by the induction of effective tumor-specific immunity. This enhanced efficacy was ablated by CD3+ T-cell depletion but was not associated with humoral immunity against the viruses.
Conclusion:
These findings show that sequential treatment of tumors with oncolytic adenovirus and vaccinia virus is a promising approach for cancer therapy and that T-cell responses play a critical role.
Insights
Sequential oncolytic virus therapy using adenovirus and vaccinia virus significantly enhances antitumor efficacy. This combination induces tumor-specific immunity and leads to complete tumor remission in a majority of treated animals.
Area of Science:
- Oncolytic virotherapy
- Cancer immunology
- Viral oncology
Background:
- Oncolytic viruses offer multifaceted antitumor mechanisms including direct lysis, improved perfusion, and immune stimulation.
- Sequential administration of distinct oncolytic viruses may overcome immune evasion and enhance therapeutic outcomes.
Purpose of the Study:
- To investigate the potential of sequential oncolytic adenovirus and vaccinia virus combination therapy.
- To evaluate if this sequential regimen can induce tumor-specific immunity and mitigate antiviral responses.
Main Methods:
- Utilized Syrian hamsters, an immune-competent model, for in vitro and in vivo studies.
- Assessed antitumor efficacy of sequential adenovirus-vaccinia virus combination against pancreatic and kidney tumors.
- Investigated mechanisms via histopathology, immunohistochemistry, CTL assays, and T-cell depletion.
Main Results:
- Sequential administration of adenovirus followed by vaccinia virus demonstrated superior efficacy over reverse order or single-virus treatment.
- 62.5% of animals achieved tumor eradication with the sequential combination, indicating robust antitumor activity.
- Therapeutic success correlated with induced tumor-specific immunity and was dependent on CD3+ T-cells, not humoral immunity.
Conclusions:
- Sequential oncolytic adenovirus and vaccinia virus treatment is a promising strategy for cancer therapy.
- T-cell-mediated immune responses are crucial for the enhanced efficacy of this sequential virotherapy approach.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...